NCT07649356 Significance of Estrogen Status for Muscle Function, Physical Fitness, and Physiological Health Parameters - a Comparison of Age-matched Groups of Women Before and After Menopause.
| NCT ID | NCT07649356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mette Hansen |
| Condition | Muscle Mass and Strength |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-02-01 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As females age and transition through menopause, the decline in oestrogen level profoundly affects skeletal muscle mass and function. HER-MUSCLE aims to unravel the differences in pre and post menopausal women, in regards to muscle size, strength and function. Focusing on postmenopausal females, an increasingly at-risk demographic, HER-MUSCLE addresses a critical gap in understanding how oestrogen influences muscle mass and function. The project involves: 1. Molecular Analysis: Advanced techniques will study the muscle microenvironment, focusing on muscle stem cells (MuSCs), fibro-adipogenic progenitors (FAPs), and other cells critical for muscle regeneration and maintenance. 2. Mitochondrial Function assessed in vivo via magnetic resonance spectroscopy: The impact of oestrogen on mitochondrial health will be examined, exploring how it preserves mitochondrial function and ability to recovery and resist fatigue in response to muscle contractions. Our preliminary data indicate that oestrogen can promote muscle protein synthesis. HER-MUSCLE aims to pave the way for novel therapeutic strategies to manage sarcopenia in postmenopausal women, ultimately leading to better health outcomes and enhanced well-being for this growing population segment.
Eligibility Criteria
Inclusion Criteria: * Regular menstrual bleeding (21-35 days cycle). * At least 9 menstrual cycles the last year * Age \>47 years old * BMI 20-30 Exclusion Criteria: * Only premenopausal women: Follicular stimulating hormone \> 30 mmol/L * Systematic strength training during the last year (\> 1 strength training session per week) * Systematic high intensity cardiovascular training during the last year (\<2 times per week) * Injuries to the legs which may prevent participation in the physical training program * Magnetizable metals or electrical devices implanted in the body, such as a pacemaker * Use of medication that can influence the effect of immobilization and/or training * Muscular or joint disorders which may affect the results * Metabolic diseases (such as diabetes and cardiovascular diseases) * Previous or present liver or cancer disease * Current or previous thrombosis * Porphyria * Epilepsia * Systemic autoimmune disease * Edema * Smoking or use of other nicotine containing products * Claustrophobia * Addictive behavior, defined as abuse of cannabis, opioids, or other intoxicating substances. * Lack of ability to cooperate * Blood parameters out of normal range at the health check * Blood pressure above 140/90 mmHg
Contact & Investigator
Mette Hansen, PhD
PRINCIPAL INVESTIGATOR
Aarhus University, Department of Public Health
Frequently Asked Questions
Who can join the NCT07649356 clinical trial?
This trial is open to female participants only, aged 47 Years or older, studying Muscle Mass and Strength. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07649356 currently recruiting?
Yes, NCT07649356 is actively recruiting participants. Contact the research team at mhan@ph.au.dk for enrollment information.
Where is the NCT07649356 trial being conducted?
This trial is being conducted at Aarhus, Denmark.
Who is sponsoring the NCT07649356 clinical trial?
NCT07649356 is sponsored by Mette Hansen. The principal investigator is Mette Hansen, PhD at Aarhus University, Department of Public Health. The trial plans to enroll 30 participants.